drugset / Trial / NCT05387668

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

NCT05387668 ↗

Phase 1 Withdrawn BeiGene
RandomizedSequentialTriple-blindTreatment

Summary

This study is designed to evaluate the influence of ethnic factors on the safety, tolerability, and pharmacokinetics (PK) of BGB-23339 after multiple dosing under fasting condition in healthy Japanese and Caucasian participants.

Timeline

Start
2022-02-17
Primary completion
2022-10-17
Completion
2022-10-17

Outcome

Outcome not reported

Stopped: “Sponsor determined the data was no longer needed.”

Drugs

EvaluationDrugModalityDoseRoute
Subject BGB-23339 Unknown — Oral

Indications

No indication recorded.